Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 2/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.43 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12950949 | 0.79 | CHRNB2 (0.57) | LSSCHRNB2CHRNA4CHRM1CHRNB4 | |
| SCHEMBL1673767 | 0.78 | LSS (0.52) | LSSCHRNB2CHRNA4CHRM1CHRM2 | |
| SCHEMBL3156325 | 0.77 | CHRNB2 (0.55) | LSSCHRNB2CHRNA4CHRM1CHRNB4 | |
| SCHEMBL10644523 | 0.77 | CHRNB4 (0.60) | LSSCHRNB2CHRNA4CHRM1CHRNB4 | |
| Hydrochloric Acid SCHEMBL10760183 | 0.75 | CHRNB4 (0.58) | LSSCHRNB2CHRNA4CHRM1CHRNB4 | |
| SCHEMBL12925945 | 0.75 | CHRNB2 (0.56) | LSSCHRNB2CHRNA4CHRM1CHRNB4 | |
| SCHEMBL9320716 | 0.72 | PTGS2 (0.41) | CHRNB4CHRNA3 | |
| SCHEMBL11862219 | 0.71 | ACMSD (0.47) | CHRNB4CHRNA3 | |
| SCHEMBL3336874 | 0.69 | — | — | |
| SCHEMBL12951373 | 0.68 | SIGMAR1 (0.50) | LSSCHRNB2CHRNA4CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308854-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Sanofi-Aventis (FR) | 2011-04-13 | — | — | EP | disclosed |
| EP-2305651-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | SANOFI (FR) | 2006-11-09 | — | — | US | disclosed |
| EP-1608630-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | PSEN1, PSEN2, MAPT | LSS 4425/4885CHRNB2 715/4885CHRNA4 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.